胶质瘤的过继细胞免疫治疗  

Adoptive Immunotherapy for Glioma

作　　者：郭建贵[1,2] 牟永告[1,2] 

机构地区：[1]华南肿瘤学国家重点实验室,广东广州510060 [2]中山大学肿瘤防治中心神经外科/神经肿瘤科,广东广州510060

出　　处：《中国神经肿瘤杂志》2013年第1期53-57,共5页Chinese Journal of Neuro-Oncology

基　　金：广东省省科技厅计划项目(NO.Z012B031800382);吴阶平基金会(NO.320 6750 12373)

摘　　要：胶质瘤是中枢神经系统最常见的原发恶性肿瘤,其预后很差,目前恶性胶质瘤患者的中位生存期仍少于15个月。免疫治疗通过激发和补充机体的抗肿瘤免疫能力来杀灭肿瘤细胞,具有特异性强、不良反应轻和长期记忆等特点,是一种较理想的治疗策略。免疫治疗包括主动免疫治疗、被动免疫治疗、基因治疗等,本文将对胶质瘤的被动免疫治疗中的过继细胞免疫治疗进展做一综述。Glioma is the most common primary malignant tumor of the central nervous system. Its prognosis is very poor. The median survival time of patients with malignant glioma is still less than 15 months. Immunotherapy which can stimulate and supplement the body＇s anti-tumor immunity to kill tumor cells with specificity, hypotoxicity and long-term memory, is an ideal treatment strategy. Immunotherapy includes active immunotherapy, passive immunotherapy and genetic immunization. In this article, we reviewed the adoptive immunotherapy for glioma.

关 键 词：胶质瘤 免疫治疗 过继免疫 

分 类 号：R739.41[医药卫生—肿瘤]